Sapphire acquires license for Novo’s obesity treatment program
These potential drug targets were identified using Novo’s proprietary computer model of the ghrelin receptor and already have shown good in vivo proof-of-concept data, according to Sapphire. William
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.